• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Commun Med (Lond) . The phylodynamics of SARS-CoV-2 during 2020 in Finland

tetano

Editor, Senior Moderator
Commun Med (Lond)


. 2022 Jun 10;2:65.
doi: 10.1038/s43856-022-00130-7. eCollection 2022.
The phylodynamics of SARS-CoV-2 during 2020 in Finland


Phuoc Truong Nguyen[SUP] #[/SUP][SUP] 1 [/SUP], Ravi Kant[SUP] #[/SUP][SUP] 1 2 [/SUP], Frederik Van den Broeck[SUP] #[/SUP][SUP] 3 4 [/SUP], Maija T Suvanto[SUP] 1 2 [/SUP], Hussein Alburkat[SUP] 1 [/SUP], Jenni Virtanen[SUP] 1 2 [/SUP], Ella Ahvenainen[SUP] 1 [/SUP], Robert Castren[SUP] 1 [/SUP], Samuel L Hong[SUP] 3 [/SUP], Guy Baele[SUP] 3 [/SUP], Maarit J Ahava[SUP] 5 [/SUP], Hanna Jarva[SUP] 5 6 7 [/SUP], Suvi Tuulia Jokiranta[SUP] 6 7 [/SUP], Hannimari Kallio-Kokko[SUP] 5 [/SUP], Eliisa Kekäläinen[SUP] 5 6 [/SUP], Vesa Kirjavainen[SUP] 5 [/SUP], Elisa Kortela[SUP] 8 [/SUP], Satu Kurkela[SUP] 5 [/SUP], Maija Lappalainen[SUP] 5 [/SUP], Hanna Liimatainen[SUP] 5 [/SUP], Marc A Suchard[SUP] 9 [/SUP], Sari Hannula[SUP] 10 [/SUP], Pekka Ellonen[SUP] 10 [/SUP], Tarja Sironen[SUP] 1 2 [/SUP], Philippe Lemey[SUP] 3 [/SUP], Olli Vapalahti[SUP] 1 2 5 [/SUP], Teemu Smura[SUP] 1 5 [/SUP]



Affiliations

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of infections and fatalities globally since its emergence in late 2019. The virus was first detected in Finland in January 2020, after which it rapidly spread among the populace in spring. However, compared to other European nations, Finland has had a low incidence of SARS-CoV-2. To gain insight into the origins and turnover of SARS-CoV-2 lineages circulating in Finland in 2020, we investigated the phylogeographic and -dynamic history of the virus.
Methods: The origins of SARS-CoV-2 introductions were inferred via Travel-aware Bayesian time-measured phylogeographic analyses. Sequences for the analyses included virus genomes belonging to the B.1 lineage and with the D614G mutation from countries of likely origin, which were determined utilizing Google mobility data. We collected all available sequences from spring and fall peaks to study lineage dynamics.
Results: We observed rapid turnover among Finnish lineages during this period. Clade 20C became the most prevalent among sequenced cases and was replaced by other strains in fall 2020. Bayesian phylogeographic reconstructions suggested 42 independent introductions into Finland during spring 2020, mainly from Italy, Austria, and Spain.
Conclusions: A single introduction from Spain might have seeded one-third of cases in Finland during spring in 2020. The investigations of the original introductions of SARS-CoV-2 to Finland during the early stages of the pandemic and of the subsequent lineage dynamics could be utilized to assess the role of transboundary movements and the effects of early intervention and public health measures.

Keywords: SARS-CoV-2; Viral epidemiology.
 
Back
Top Bottom